New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol

References

• Qaseem A Wilt TJ Weinberger SE American College of Physicians American College of Chest Physicians American Thoracic Society European Respiratory Society Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society Ann Intern Med 2011 155 179 191 21810710
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html Accessed June 20, 2013
   Google Scholar
• Cazzola M Page CP Calzetta L Matera MG Pharmacology and therapeutics of bronchodilators Pharmacol Rev 2012 64 450 504 22611179
   PubMed Web of Science ®Google Scholar
• Cazzola M Brusasco V Centanni S Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists Pulm Pharmacol Ther 2013 26 218 228 23147424
   PubMed Web of Science ®Google Scholar
• Cazzola M Tashkin DP Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function COPD 2009 6 404 415 19863370
   PubMedGoogle Scholar
• van der Molen T Cazzola M Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes Prim Care Respir J 2012 21 101 108 22222945
   PubMedGoogle Scholar
• Wedzicha JA Decramer M Ficker JH Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study Lancet Respir Med 2013 1 199 209
   PubMed Web of Science ®Google Scholar
• Donohue JF Combination therapy for chronic obstructive pulmonary disease: clinical aspects Proc Am Thorac Soc 2005 2 272 281 16267348
   PubMedGoogle Scholar
• Cazzola M Molimard M The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD Pulm Pharmacol Ther 2010 23 257 267 20381630
   PubMed Web of Science ®Google Scholar
• Cazzola M Calzetta L Matera MG β2-adrenoceptor agonists: current and future direction Br J Pharmacol 2011 163 4 17 21232045
   PubMed Web of Science ®Google Scholar
• Meurs H Oenema TA Kistemaker LE Gosens R A new perspective on muscarinic receptor antagonism in obstructive airways diseases Curr Opin Pharmacol 2013 13 316 323 23643733
   PubMed Web of Science ®Google Scholar
• Meurs H Dekkers BG Maarsingh H Halayko AJ Zaagsma J Gosens R Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target Pulm Pharmacol Ther 2013 26 145 155 22842340
   PubMed Web of Science ®Google Scholar
• Ahmedat AS Warnken M Juergens UR Paul Pieper M Racké K β2-adrenoceptors and muscarinic receptors mediate opposing effects on endothelin-1 expression in human lung fibroblasts Eur J Pharmacol 2012 691 218 224 22796455
   PubMed Web of Science ®Google Scholar
• Profita M Bonanno A Montalbano AM β2 long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD Biochim Biophys Acta 2012 1822 1079 1089 22440430
   PubMed Web of Science ®Google Scholar
• Tashkin DP Ferguson GT Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease Respir Res 2013 14 49 23651244
   PubMed Web of Science ®Google Scholar
• Matera MG Page CP Cazzola M Novel bronchodilators for the treatment of chronic obstructive pulmonary disease Trends Pharmacol Sci 2011 32 495 506 21683458
   PubMed Web of Science ®Google Scholar
• Cazzola M Rogliani P Segreti A Matera MG An update on bronchodilators in Phase I and II clinical trials Expert Opin Investig Drugs 2012 21 1489 1501
   PubMed Web of Science ®Google Scholar
• Cazzola M Page CP Rogliani P Matera MG β2-agonist therapy in lung disease Am J Respir Crit Care Med 2013 187 690 696 23348973
   PubMed Web of Science ®Google Scholar
• Cazzola M Rogliani P Matera MG Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease Expert Opin Pharmacother 2013 14 775 781 23472632
   PubMed Web of Science ®Google Scholar
• Salmon M Luttmann MA Foley JJ Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases J Pharmacol Exp Ther 2013 345 260 270 23435542
   PubMed Web of Science ®Google Scholar
• Tal-Singer R Cahn A Mehta R Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies Eur J Pharmacol 2013 701 40 48 23276660
   PubMed Web of Science ®Google Scholar
• Cahn A Tal-Singer R Pouliquen IJ Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies Clin Drug Investig 2013 33 477 488
   PubMed Web of Science ®Google Scholar
• Decramer M Maltais F Feldman G Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients Respir Physiol Neurobiol 2013 185 393 399 23026438
   PubMed Web of Science ®Google Scholar
• Donohue JF Anzueto A Brooks J Mehta R Kalberg C Crater G A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD Respir Med 2012 106 970 979 22498110
   PubMed Web of Science ®Google Scholar
• Slack RJ Barrett VJ Morrison VS In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action J Pharmacol Exp Ther 2013 344 218 230 23131596
   PubMed Web of Science ®Google Scholar
• Harrell AW Siederer SK Bal J Metabolism and disposition of vilanterol, a long-acting β2-adrenoceptor agonist for inhalation use in humans Drug Metab Dispos 2013 41 89 100 23043183
   PubMed Web of Science ®Google Scholar
• Kempsford R Norris V Siederer S Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD Pulm Pharmacol Ther 2013 26 256 264 23232038
   PubMed Web of Science ®Google Scholar
• Hanania NA Feldman G Zachgo W The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial Chest 2012 142 119 127 22241764
   PubMed Web of Science ®Google Scholar
• Kelleher DL Mehta RS Jean-Francois BM Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial PLoS One 2012 7 e50716 23284643
   PubMed Web of Science ®Google Scholar
• Kelleher D Tombs L Crater G Preece A Brealey N Mehta R A placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects Am J Respir Crit Care Med 2013 187 A1487
   Web of Science ®Google Scholar
• Feldman G Walker RR Brooks J Mehta R Crater G 28-day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial Pulm Pharmacol Ther 2012 25 465 471 22955035
   PubMed Web of Science ®Google Scholar
• Donohue JF Maleki-Yazdi M Kilbride S Mehta R Kalberg CJ Church A ride S Mehta R Kalberg C Church A Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD Respir Med 2013 7 2 [Epub ahead of print]
   Web of Science ®Google Scholar
• Celli BR Crater G Kilbride S A 24-week randomized, doubleblind, placebo-controlled study of the efficacy and safety of once-daily umeclidinium/vilanterol 125/25 mcg in COPD Am J Respir Crit Care Med 2013 187 A2435
   Google Scholar
• Anzueto A Decramer M Kaelin T The efficacy and safety of umeclidinium/vilanterol compared with tiotropium or vilanterol over 24 weeks in subjects with COPD Am J Respir Crit Care Med 2013 187 A4268
   Web of Science ®Google Scholar
• Cazzola M Page C Matera MG Long-acting muscarinic receptor antagonists for the treatment of respiratory disease Pulm Pharmacol Ther 2013 26 307 317 23274274
   PubMed Web of Science ®Google Scholar
• Charlton SJ Agonist efficacy and receptor desensitization: from partial truths to a fuller picture Br J Pharmacol 2009 158 165 168 19719779
   PubMed Web of Science ®Google Scholar
• D’Urzo AD De Salvo MC Ramirez-Rivera A In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study Chest 2001 119 1347 1356 11348938
   PubMed Web of Science ®Google Scholar
• Restrepo RD Alvarez MT Wittnebel LD Medication adherence issues in patients treated for COPD Int J Chron Obstruct Pulmon Dis 2008 3 371 384 18990964
   PubMedGoogle Scholar
• Wu K Looby M Pillai G Pinault G Drollman AF Pascoe S Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients J Pharmacokinet Pharmacodyn 2011 38 105 119 21104005
   PubMed Web of Science ®Google Scholar
• Church A Kalberg C Shah P Beerahee M Donohue J An analysis of the dose response of umeclidinium (GSK573719) administered once or twice daily in patients with COPD Chest 2012 142 672A
   Google Scholar
• Sterling R Lim J Frith L Snowise NG Jacques L Haumann B Efficacy and optimal dosing interval of the long-acting beta2 agonist, vilanterol, in persistent asthma: a randomised trial Respir Med 2012 106 1110 1115 22520084
   PubMed Web of Science ®Google Scholar